Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 269 Results

June 15, 2015

Relmada Therapeutics to Present at 2015 BIO International Convention

June 10, 2015

Relmada Therapeutics Successfully Completes Phase 1 Single Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone

May 27, 2015

Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference

May 19, 2015

Relmada Therapeutics to Present at the 2015 Marcum MicroCap Conference

May 12, 2015

Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering SECUREL(TM), its Abuse-Deterrent, Extended-Release, Technology Platform for Opioids

April 21, 2015

Relmada Therapeutics Commences Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine

April 16, 2015

Relmada Therapeutics Receives Health Canada Clearance to Further Explore Promising NMDA Receptor Antagonist d-Methadone (REL-1017)

April 8, 2015

Relmada Therapeutics Appoints Lisa Nolan, Ph.D. as Senior Vice President of Business Development

April 2, 2015

Relmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market

March 24, 2015

Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine

«...22 232425 26 27

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top